The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in patients with type 2 diabetes.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [4]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294
Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 2
- Toto RD, 2013, J Am Soc Nephrol, 24
- 10.1056/NEJMsr077003 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 698
McAdam-Marx, C., White, K. N., & Gurgle, H. E. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83088 · Cited by 46
Song, Y., Tan, Y., Deng, M., Shan, W., Zheng, W., Zhang, B., Cui, J., Feng, L., Shi, L., Zhang, M., et al. (2023) · MedComm · doi:10.1002/mco2.413 · Cited by 48
The double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 52
Epigenetic Therapies for Heart Failure: Current Insights and Future Potential
Claudio Napoli, A., Bontempo, P., Palmieri, V., Coscioni, E., Maiello, C., Donatelli, F., & Benincasa, G. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s287082 · Cited by 42
Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
Kalra, S., Jain, A., Ved, J., & Unnikrishnan, A. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.183826 · Cited by 42
Couselo‐Seijas, M., Agra-Bermejo, R. M., Fernández, Á. L., Martínez‐Comendador, J. M., Sierra, J., Pérez, M. S., Rozados-Luís, A., González‐Juanatey, J. R., & Eirás, S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.11.016 · Cited by 44
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Efficacy and safety of empagliflozin for type 2 diabetes mellitus
Zhang, Y., Han, S., Sun, X., Wang, S., Wang, H., Liu, X., Chen, L., & Xia, L. (2018) · Medicine · doi:10.1097/md.0000000000012843 · Cited by 40
Shepard, B. D., Koepsell, H., & Pluznick, J. L. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00069.2018 · Cited by 40
Zhang, J., Huan, Y., Leibensperger, M. R., Seo, B., & Song, Y. (2022) · Kidney360 · doi:10.34067/kid.0006672021 · Cited by 44
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME
Sarafidis, P. A., Lazaridis, A. A., Ruiz‐Hurtado, G., & Ruilope, L. M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.209 · Cited by 40
Self-citationGorica, E., Mohammed, S. A., Ambrosini, S., Calderone, V., Costantino, S., & Paneni, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.923014 · Cited by 39
Rahman, H., Khan, S. U., Lone, A. N., Ghosh, P., Kunduru, M., Sharma, S., Sattur, S., & Kaluski, E. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030578 · Cited by 38
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Yokose, C., McCormick, N., Abhishek, A., Dalbeth, N., Pascart, T., Lioté, F., Gaffo, A., FitzGerald, J. D., Terkeltaub, R. A., Sise, M. E., et al. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01092-x · Cited by 42
Edmonston, D. L., Mulder, H. S., Lydon, E. J., Chiswell, K., Lampron, Z. M., Shay, C. M., Marsolo, K. A., Shah, R. C., Jones, W. S., Gordon, H. S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.016 · Cited by 42
Lahoti, S., Nashawi, M., Sheikh, O., Massop, D., Mir, M., & CHILTON, R. J. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000209 · Cited by 40
Yang, A., Wu, H., Lau, E. S. H., Zhang, X., Shi, M., Fan, B., Ronald, C. W., Kong, A. P. S., Luk, A. O. Y., Chan, J. C. N., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100509 · Cited by 37
Qian, P., Tian, H., Wang, Y., Lu, W., Li, Y., Ma, T., Gao, X., & Yao, W. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114209 · Cited by 36
Aroor, A. R., Manrique‐Acevedo, C., & DeMarco, V. G. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0704-1 · Cited by 37
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
(2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.011 · Cited by 36
Adjunctive therapy for glucose control in patients with type 1 diabetes
Harris, K., Boland, C. L., Meade, L. T., & Battise, D. M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141700 · Cited by 34
Disruption of energy utilization in diabetic cardiomyopathy; a mini review
Nirengi, S., da Silva, C. P. V., & Stanford, K. I. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.015 · Cited by 35
Iordan, L., Gaiţă, L., Timar, R. Z., Avram, V. F., Sturza, A., & Timar, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137057 · Cited by 34
Brown, A., Lang, C. C., McCrimmon, R. J., & Struthers, A. D. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0663-6 · Cited by 33
Mancinetti, F., Xenos, D., Fano, M. D., Mazzieri, A., Porcellati, F., Boccardi, V., & Mecocci, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102018 · Cited by 33
Wood, N., Straw, S., Scalabrin, M., Roberts, L. D., Witte, K. K., & Bowen, T. S. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13121 · Cited by 31
Yanai, H., Katsuyama, H., Hamasaki, H., Adachi, H., Moriyama, S., Yoshikawa, R., & Sako, A. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2385w · Cited by 31
Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon
Tanrıöver, C., Uçku, D., Akyol, M., Çevik, E., Kanbay, A., Sridhar, V. S., Cherney, D. Z. I., & Kanbay, M. (2022) · Sleep And Breathing · doi:10.1007/s11325-022-02606-1 · Cited by 35
Weir, M. R., McCullough, P. A., Buse, J. B., & Anderson, J. E. (2020) · American Journal of Nephrology · doi:10.1159/000506533 · Cited by 31
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 36
Scholtes, R. A., Muskiet, M. H. A., van Baar, M. J. B., Hesp, A. C., Greasley, P. J., Hammarstedt, A., Karlsson, C., Hallow, K. M., Danser, A. H. J., Heerspink, H. J. L., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.02.023 · Cited by 30
Yanai, H., Hakoshima, M., Adachi, H., Kawaguchi, A., Waragai, Y., Harigae, T., Masui, Y., Kakuta, K., Hamasaki, H., Katsuyama, H., et al. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3046w · Cited by 31
Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
Chen, L., Ma, S., Hu, D., Lin, H., Zhu, Y., Chen, K., Chen, L., Zheng, C., Liu, J., & Liao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.561494 · Cited by 29
Hu, S., Lin, C., Cai, X., Zhu, X., Lv, F., Nie, L., & Ji, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.814074 · Cited by 29
Severino, P., D’Amato, A., Prosperi, S., Fanisio, F., Birtolo, L. I., Costi, B., Netti, L., Chimenti, C., Lavalle, C., Maestrini, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147650 · Cited by 30
Belli, M., Barone, L., Bellia, A., Sergi, D., Lecis, D., Prandi, F. R., Milite, M., Galluccio, C., Muscoli, S., Romeo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314598 · Cited by 29
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 28
Yabiku, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.768850 · Cited by 27
The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe, Y., & Vallon, V. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020032 · Cited by 29
Wei, J., Tan, F., Long, X., Fang, Q., Wang, Y., Wang, J., He, J., Yuan, X., & Du, J. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106531 · Cited by 27
Zhang, L., Xue, S., Hou, J., Chen, G., & Xu, Z. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i11.553 · Cited by 26
Wang, X., Wang, Z., Liu, D., Jiang, H., Cai, C., Li, G., & Yu, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.839640 · Cited by 27
Frontier and Hotspot Evolution in Cardiorenal Syndrome: A Bibliometric Analysis From 2003 to 2022
Lv, J., Li, Y., Shi, S., Liu, S., Xu, X., Wu, H., Zhang, B., & Song, Q. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101238 · Cited by 26
Mohammed, A., Abdu, F. A., Liu, L., Yin, G., Mareai, R. M., Mohammed, A. A. S., Xu, Y., & Che, W. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.07.016 · Cited by 26
Inagaki, N., Goda, M., Yokota, S., Maruyama, N., & Iijima, H. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0255-8 · Cited by 26
Kalra, S., Ghosh, S. K., Aamir, A., Ahmed, M. T., Amin, M. F., Bajaj, S., Baruah, M., Bulugahapitiya, U., Das, A., Giri, M., et al. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196029 · Cited by 26
Zhao, D., Liu, H., & Dong, P. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0134-2 · Cited by 26
Magurno, M., Cassano, V., Maruca, F., Pastura, C. A., Divino, M., Fazio, F., Severini, G., Clausi, E., Armentaro, G., Miceli, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168811 · Cited by 25
Sodium glucose cotransporters inhibitors in type 1 diabetes
Dellepiane, S., Nasr, M. B., Assi, E., Usuelli, V., Letizia, T., D’Addio, F., Zuccotti, G., & Fiorina, P. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.018 · Cited by 26
The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Loutradis, C., Papadopoulou, E., Angeloudi, E., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191029111713 · Cited by 25
Self-citationJenkins, A. L., Morgan, L., Bishop, J., Jovanovski, E., Jenkins, D. J. A., & Vuksan, V. V. V. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1496-x · Cited by 28
Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
John, M., Gopinath, D., & Jagesh, R. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.172268 · Cited by 24
Kugler, A. J., & Thiman, M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s134960 · Cited by 24
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eirás, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 26
Kawata, T., Iizuka, T., Iemitsu, K., Takihata, M., Takai, M., Nakajima, S., Minami, N., Umezawa, S., Kanamori, A., Takeda, H., et al. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3038w · Cited by 24
SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot
Sawicki, K. T., Ben‐Sahra, I., & McNally, E. M. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021949 · Cited by 24
Neeland, I. J., McGuire, D. K., Eliasson, B., Ridderstråle, M., Zeller, C., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0146-7 · Cited by 24
Furuhashi, M., Matsumoto, M., Hiramitsu, S., Omori, A., Tanaka, M., Moniwa, N., Yoshida, H., Ishii, J., & Miura, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154482 · Cited by 23
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip
Luconi, M., Cantini, G., Ceriello, A., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.126 · Cited by 24
Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection
Requena-Ibáñez, J. A., Santos‐Gallego, C. G., Rodriguez-Cordero, A., Zafar, M. U., & Badimón, J. J. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07257-0 · Cited by 23
Yin, Z., Zheng, H., & Guo, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.902923 · Cited by 22
Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
Voorrips, S. N., Saucedo‐Orozco, H., Sánchez-Aguilera, P., de Boer, R. A., van der Meer, P., & Westenbrink, B. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158631 · Cited by 24
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives
Nevola, R., Villani, A., Imbriani, S., Alfano, M., Criscuolo, L., Beccia, D., Ruocco, R., Femine, A. D., Gragnano, F., Cozzolino, D., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805103 · Cited by 25
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 22
Cherukuri, L., Smith, M. S., & Tayek, J. A. (2018) · doi:10.31038/edmj.2018232 · Cited by 21
Tratamento farmacológico da hiperglicemia no DM2
Filho, R. L. D. S., Albuquerque, L., Cavalcanti, S. M., Tambascia, M. A., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-10 · Cited by 33
Chi, B., Zou, A., Mao, L., Cai, D., Xiao, T., Wang, Y., Wang, Q., Ji, Y., & Sun, L. V. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/7747727 · Cited by 22
Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
Gotzmann, M., Henk, P., Stervbo, U., Blazquez‐Navarro, A., Mügge, A., Babel, N., & Westhoff, T. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134458 · Cited by 21
Ko, H. Y., Bea, S., Jeong, H. E., Park, S., Cho, Y. M., Kong, S. H., & Shin, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.35797 · Cited by 24
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
Hinnen, D. A., & Kruger, D. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188705 · Cited by 23
Yu, H., Basu, S., & Hallow, K. M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008074 · Cited by 22
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 24
Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
Delanaye, P., Wissing, K. M., & Scheen, A. J. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab096 · Cited by 21
Role of metformin in the management of type 2 diabetes: recent advances
Gonzalez-Lopez, C., & Wojeck, B. S. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16511 · Cited by 26
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes
Neeland, I. J., Salahuddin, U., & McGuire, D. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1135900 · Cited by 20
Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice
Abdurrachim, D., Manders, E., Nicolay, K., Mayoux, E., & Prompers, J. J. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy246 · Cited by 20
Practical combination therapy based on pathophysiology of type 2 diabetes
LEVIN, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s109216 · Cited by 21
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Srivastava, S. P., Srivastava, R., Chand, S., & Goodwin, J. E. (2021) · Pharmaceuticals · doi:10.3390/ph14080751 · Cited by 20
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
Matthews, J. R., Herat, L. Y., Schlaich, M. P., & Matthews, V. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814243 · Cited by 19
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Anderson, J. E., Wright, E. E., & Shaefer, C. F. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0211-x · Cited by 19
Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control
Baruah, M., Makkar, B. M., Ghatnatti, V., & Mandal, K. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_160_17 · Cited by 19
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 19
Loutradis, C., Papadopoulou, E., Theodorakopoulou, M. P., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0514 · Cited by 21
Self-citationMonteiro, P. F., Aguíar, C., Matos, P. L. P., Silva‐Nunes, J., Birne, R., Branco, P. Q., Calado, J., Melo, M., & Polónia, J. J. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.02.015 · Cited by 18
Tang, Y., & Sang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1030642 · Cited by 18
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
Thompson, G., & Hershon, K. S. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s100288 · Cited by 18
Suvarna, V. R., Gupta, S., Shaikh, S. S., Joshi, P., & Bhure, S. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_517_16 · Cited by 18
Domon, A., Katayama, K., Sato, T., Tochigi, Y., Tazaki, H., & Suzuki, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251135 · Cited by 18
Abdelgadir, E., Rashid, F., Bashier, A. M., & Ali, R. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3467w · Cited by 18
Huang, J., Liu, Y., Shi, M., Zhang, X., Zhong, Y., Guo, S., Ma, Y., Pan, L., Yang, F., & Wang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117589 · Cited by 17
Du, J., Liu, J., Wang, X., Wang, X., Ma, Y., Zhang, S., Li, Z., Ma, J., & Liu, J. (2025) · Biology Direct · doi:10.1186/s13062-025-00618-x · Cited by 22
Gelbenegger, G., Buchtele, N., Schoergenhofer, C., Roeggla, M., & Schwameis, M. (2017) · Drug Safety - Case Reports · doi:10.1007/s40800-017-0058-8 · Cited by 17
Kurtz, R., Libby, A. E., Jones, B. A., Myakala, K., Wang, X., Lee, Y., Knoer, G., Cascio, J. N. L., McCormack, M., Nguyen, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105675 · Cited by 17
Liberale, L., Kraler, S. C., Puspitasari, Y. M., Bonetti, N. R., Akhmedov, A. T., Ministrini, S., Montecucco, F., Marx, N., Lehrke, M., Hartmann, N. K., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac126 · Cited by 17
Management standards for stable coronary artery disease in India
Mishra, S., Ray, S., Dalal, J. J., Sawhney, J. P. S., Ramakrishnan, S., Nair, T., Iyengar, S. S., & Bahl, V. K. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.11.320 · Cited by 17
Ketone body metabolism in diabetic and non-diabetic heart failure
Qian, N., & Wang, Y. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09857-3 · Cited by 17
Alfonso, C. O. C., & Centurión, O. A. (2019) · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · doi:10.18004/rvspmi/2312-3893/2019.06(01)75-085 · Cited by 16
Prescription Patterns of Novel Antihyperglycemic Medications
Ali, A. S., Khan, M., Ortega, D., Jaffery, S. H., Lamerato, L. E., & Budzynska, K. (2022) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2022.02.210360 · Cited by 16
The management of acute and chronic hyponatraemia
Lawless, S. J., Thompson, C. J., & Garrahy, A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221097343 · Cited by 22
Metadata
- Authors
- Sarafidis, P. A., & Τσάπας, Α.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-17
- Volume
- 374
- Issue
- 11
- Pages
- 1092-1094
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2297835124
- Cited by
- 700
- References
- 9
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 77 · 2023: 91 · 2022: 71 · 2021: 95 · 2020: 93 · 2019: 61 · 2018: 57 · 2017: 62 · 2016: 34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, type 2 diabetes, cardiovascular outcomes, mortality, SGLT2 inhibitors, cardiovascular risk reduction
- MeSH terms
- Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
